Dulaglutide

What it is

Dulaglutide is not a simple short peptide. The March 2026 Trulicity label describes two identical linked chains, each joining a modified GLP-1 sequence to part of a human IgG4 antibody. LY2189265 is the development code. Trulicity is the approved finished product.

The approved record is for the labeled sterile subcutaneous Trulicity product. A shared ingredient name does not establish the formulation, concentration, device, excipients, manufacturing controls, sterility, stability, storage history, or approval of another product.

Why people care

Dulaglutide is an established GLP-1 receptor agonist with randomized glycemic and cardiovascular outcomes evidence. Reader questions often collapse that exact record into class-wide weight-loss claims or assume that any product carrying the ingredient name is equivalent to Trulicity.

What humans actually show

Dulaglutide is the active ingredient in the FDA-approved prescription product Trulicity. The March 2026 United States label reviewed for this packet covers glycemic control in adults and children aged 10 years and older with type 2 diabetes and reduction of major cardiovascular-event risk in defined adults with type 2 diabetes. That approval does not establish dulaglutide as an approved general weight-loss product or authenticate a compounded or unidentified product.

• approved label — Adults and pediatric patients aged 10 years and older with type 2 diabetes in the product's labeled clinical program; Route: Subcutaneous Trulicity; Outcome: Glycemic control and, in a defined adult population, major adverse cardiovascular events: The label supports product-specific indications for glycemic control and cardiovascular risk reduction in the stated populations. The seam: The indications are limited to the labeled populations and product; The label does not approve dulaglutide for general chronic weight management; The approved record cannot authenticate another formulation or product.
• randomized human — 9,901 adults aged at least 50 years with type 2 diabetes and either previous cardiovascular disease or cardiovascular risk factors; Route: Weekly subcutaneous dulaglutide or placebo added to existing antihyperglycemic regimens; Outcome: First cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke over a median 5.4 years: The primary outcome occurred in 12.0% of dulaglutide participants and 13.4% of placebo participants; the reported hazard ratio was 0.88 with a 95% confidence interval of 0.79 to 0.99. The seam: The result applies to the trial's type 2 diabetes population and composite endpoint; It does not establish the same effect for people without type 2 diabetes; It does not establish a chronic-weight-management indication; A relative treatment effect does not predict an individual outcome.
• randomized human — 154 participants aged 10 to under 18 years with type 2 diabetes and elevated body-mass index using lifestyle measures with or without metformin or basal insulin; Route: Weekly subcutaneous dulaglutide or placebo for 26 weeks, followed by an open-label extension; Outcome: Change in glycated hemoglobin, glycemic targets, fasting glucose, body-mass index, and safety: Dulaglutide improved glycemic control versus placebo at 26 weeks. The trial reported no between-group difference in body-mass-index change, and gastrointestinal adverse events were more frequent with dulaglutide. The seam: The controlled period was 26 weeks; The study addressed youth with type 2 diabetes, not general pediatric weight management; The study did not show a body-mass-index effect at the primary assessment.

Mechanistic and nonhuman evidence

• mechanistic — Labeled pharmacology record; Route: Subcutaneous labeled product; Outcome: GLP-1 receptor activation, glucose-dependent insulin release, glucagon secretion, and gastric emptying: The label describes increased glucose-dependent insulin release, decreased glucagon secretion, and slowed gastric emptying. The seam: A pharmacologic mechanism does not establish an unapproved clinical use; Mechanistic similarity does not make different GLP-1 products interchangeable; Slowed gastric emptying also creates interaction and procedural-safety boundaries.
• animal — Lifetime exposure studies in male and female rats summarized in the label; Route: Dulaglutide exposure in animals; Outcome: Thyroid C-cell tumors: The label reports a treatment-duration-dependent and exposure-related increase in thyroid C-cell tumors in rats. The seam: The label states that the relevance of the rodent finding to humans is unknown; Animal findings do not quantify an individual human risk; The finding supports a boxed warning and contraindications, not an efficacy claim.

FDA and U.S. status

The March 2026 Trulicity label is FDA approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, and to reduce major adverse cardiovascular-event risk in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. The label does not include a chronic-weight-management indication. The openFDA exact-substance record, last updated July 28, 2026, lists BLA125469 products with Prescription marketing status.

Risks and warning limits

• approved label: The label carries a boxed warning for thyroid C-cell tumors observed in rats and contraindicates Trulicity in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
• approved label: Labeled warnings include acute pancreatitis, hypoglycemia when used with insulin secretagogues or insulin, serious hypersensitivity, acute kidney injury due to volume depletion, severe gastrointestinal reactions, diabetic-retinopathy complications, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation.
• human trial: The most common labeled adverse reactions are nausea, diarrhea, vomiting, abdominal pain, and decreased appetite.

What remains unknown

• The cited evidence does not establish dulaglutide as a general chronic-weight-management treatment outside the exact approved indications.
• The human relevance of the rodent thyroid C-cell tumor finding remains unknown in the current label.
• The identity, potency, sterility, stability, and excipient profile of a compounded or unidentified product cannot be inferred from the word dulaglutide.

Product identity and quality limits

• Trulicity is a specific approved fusion-protein drug product; the name dulaglutide alone does not establish the product, device, formulation, or quality controls.
• FDA states that compounded drugs are not FDA approved. The Trulicity label cannot be transferred to a compounded or unidentified material.

What has been studied together

• Dulaglutide with insulin secretagogues or insulin — known label boundary: The label states that concomitant use can increase hypoglycemia risk. This is a product-label risk boundary, not general compatibility clearance for a reader or for other combinations.
• Dulaglutide with orally administered medicines — known label boundary: Because dulaglutide delays gastric emptying, the label states that it can reduce the rate of absorption of concomitantly administered oral medicines. The label record is medicine-specific and does not establish that every oral coadministration is clinically consequential or safe.

What people are hearing

These are claims this profile checks, not established conclusions.

• Claim under review: “Because dulaglutide is a GLP-1 receptor agonist, it is FDA approved for general chronic weight management.”
• Claim under review: “The cardiovascular indication means dulaglutide has proven the same outcome in every person or every GLP-1 use.”
• Claim under review: “A product called dulaglutide is automatically the same as the approved Trulicity product.”

Questions readers raise

• No reproducible community sample was collected for this profile.

The community-signal layer is not efficacy or safety evidence. Its current limits are:

• No reproducible community sample has been collected for this profile.
• Self-reports would be subject to selection and reporting bias.
• The identity of a product described in a self-report could not be verified.
• Concurrent medicines, health conditions, diet, and behavior could confound an anecdote.
• Reported outcomes could not be independently verified.
• Anecdotes cannot establish efficacy, safety, approval, product identity, or interaction compatibility.

What would change this answer

• A revised FDA label or new approval action would change the exact United States indication or warning boundary.
• Large controlled trials in a clearly defined non-diabetes population with patient-important outcomes would be required before extending conclusions beyond the studied populations.
• Product-specific analytical and manufacturing evidence would be required to assess an unidentified material; a shared ingredient name is insufficient.

Sources and records

• WADA — 2026 Prohibited List

• TRULICITY (dulaglutide) prescribing information, revised March 2026 — U.S. Food and Drug Administration
• Drugs@FDA API exact active-ingredient search for dulaglutide — U.S. Food and Drug Administration
• Compounding and the FDA: Questions and Answers — U.S. Food and Drug Administration
• ClinicalTrials.gov intervention search for dulaglutide — ClinicalTrials.gov
• PubMed search for dulaglutide in human records — National Library of Medicine
• Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial — PubMed
• REWIND trial registry record — ClinicalTrials.gov
• Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes — PubMed
• AWARD-PEDS trial registry record — ClinicalTrials.gov